Metamizol for the Treatment of Neoplastic Chronic Pain
Phase 4
Terminated
- Conditions
- Pain
- Interventions
- Registration Number
- NCT02181920
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Study to evaluate the efficacy of metamizole in reducing morphine requirements in patients with moderate to severe chronic cancer pain in comparison to administration of placebo or diclofenac.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
- Hospitalized patients with neoplastic chronic pain requiring morphine treatment
Exclusion Criteria
- Karnofsky index less than 30%
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Placebo - Metamizole Metamizole placebo followed by metamizole Metamizole - Diclofenac Diclofenac metamizole followed by diclofenac Diclofenac - Metamizole Metamizole diclofenac followed by metamizole Diclofenac - Metamizole Diclofenac placebo diclofenac followed by metamizole Metamizole - Placebo Diclofenac placebo metamizole followed by placebo Metamizole - Placebo Metamizole placebo metamizole followed by placebo Placebo - Metamizole Metamizole placebo placebo followed by metamizole Metamizole - Diclofenac Metamizole metamizole followed by diclofenac Diclofenac - Metamizole Metamizole placebo diclofenac followed by metamizole Metamizole - Diclofenac Diclofenac placebo metamizole followed by diclofenac Metamizole - Diclofenac Metamizole placebo metamizole followed by diclofenac Placebo - Metamizole Diclofenac placebo placebo followed by metamizole Diclofenac - Metamizole Diclofenac diclofenac followed by metamizole Metamizole - Placebo Metamizole metamizole followed by placebo
- Primary Outcome Measures
Name Time Method Change in morphine requirement Baseline, 9 days
- Secondary Outcome Measures
Name Time Method